-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $940

Benzinga·04/30/2025 17:46:20
Listen to the news
Truist Securities analyst Srikripa Devarakonda maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and lowers the price target from $975 to $940.